The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)

April 26, 2017 updated by: TCM Biotech International Corp.

A Phase III, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effects of Adding TCM-700C,Botanical Drug, on the Standard Treatment (Peginterferon and Ribavirin) for Subjects With Naive Genotype 1 Hepatitis C Infection

This is a randomized, double blind, multi-center, placebo controlled, three parallel arms, Phase IIb/III clinical study to evaluate the effects of adding a TCM-700C with a low or high dose onto the combination treatment (PegIFN plus RBV) for subjects with naive genotype 1 HCV infection.

This will be demonstrated by a higher sustained virologic response rate, defined as the absence of detectable HCV RNA 24 weeks after the termination of combination treatment, compared with the placebo add-on.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

Eligible subjects with written informed consent will be stratified according to their baseline HCV RNA (≤800,000 IU/mL versus>800,000 IU/mL), stage of liver fibrosis (METAVIR system fibrosis score of 0 1 versus 2 3).

During the 48 week Treatment Period and 24 week Follow up Period, subjects will be assessed at regular intervals for efficacy and safety at Weeks 2, 4, 8, 12, 16 and then every 8 weeks thereafter until study completion. If possible, subjects who prematurely discontinue the study during the Treatment Period will have samples taken for hematology, biochemistry and urinalysis in the same week of discontinuation as well as 24 weeks after discontinuation.

Study Type

Interventional

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100044
        • Peking University People's Hospit
  • Taiwan
      • Taoyuan, Taiwan, 333
        • Chang Gung Memorial Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult subjects who are 20 to 65 years old (inclusive), of either gender and in any ethnical group in Asia.
  • Chronic hepatitis C, positive with both antibody to hepatitis C virus (anti HCV) and HCV RNA assays.
  • Confirmed HCV genotype 1.
  • Subjects who are indicated to have combination treatment of PegIFNα 2a and RBV at the discretion of the investigator.
  • All fertile males and females receiving RBV must be using two forms of effective contraception during treatment with study drugs and 6 months post treatment completion.
  • Subjects must voluntarily give written informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
  • Subjects must be able to comply with the assessments during the study.
  • Subjects must be able to understand study QoL questionnaires.

Exclusion Criteria:

  • Prior treatment with any IFN α or any medicines that contain Cordyceps.
  • Prior treatment of hepatitis C with any other antiviral or immune modulators.
  • Investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study.
  • Subjects diagnosed with hepatocellular carcinoma (HCC) by biopsy or α fetoprotein (AFP) serology and radiology (helical computed tomography [CT] and/or magnetic resonance imaging [MRI]) within 5 years of signing the informed consent form.
  • Evidence of hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy).
  • History or evidence of other liver diseases other than chronic HCV infection.
  • Subjects with known allergy or hypersensitivity to any ingredient of the study drug or placebo.
  • Pregnant, planning on becoming pregnant, or breastfeeding female subject or male subject whose partner is pregnant or planning on becoming pregnant.

  • Subject with any of the following laboratory abnormalities:

    1. Platelet count <90,000/mm3;
    2. Absolute neutrophil count <1500 cells/mm3;
    3. Hemoglobin <12 g/dL for women and <13 g/dL for men;
    4. Creatinine >1.5 mg/dL;
    5. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >10 x upper limit of normal (ULN);
    6. Total serum bilirubin >1.5 x ULN;
    7. Subjects without cirrhosis and AFP >50 ng/mL must have an ultrasound between the screening and baseline visit with no findings suspicious for HCC.

  • Medical conditions which are contraindications for PegIFNα 2a or RBV therapy:

    1. Psychiatric disorders;
    2. Organ transplant (other than cornea or hair transplant or skin graft);
    3. Severe concurrent medical disease such as severe hypertension, significant coronary heart disease, poorly controlled diabetes mellitus (glycated hemoglobin A1c [HbA1c] >8.5%), not adequately controlled thyroid dysfunction, chronic obstructive pulmonary disease, severe infections (bacterial, viral, fungal, including acute tuberculosis), or hemoglobinopathies (thalassemia major or sickle cell anemia);
    4. Autoimmune hepatitis or other autoimmune conditions known to be exacerbated by PegIFNα 2a and RBV.
  • History of a severe seizure disorder or current anticonvulsant use.
  • Evidence of severe retinopathy (e.g., cytomegalovirus retinitis, macular degeneration) or clinically relevant ophthalmological disorder (e.g., due to diabetes mellitus or hypertension).
  • Other cases judged by the investigator to be ineligible for participation in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TCM-700C (low dose)
an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
Drug: TCM-700C
An add-on drug to conventional treatment of Hepatitis C
Drug: Peginterferon alfa-2a
conventional treatment of Hepatitis C
Other Names:
  • Pegasys
Drug: Ribavirin
conventional treatment of Hepatitis C
Other Names:
  • Rebetol
Experimental: TCM-700C (high dose)
an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
Drug: TCM-700C
An add-on drug to conventional treatment of Hepatitis C
Drug: Peginterferon alfa-2a
conventional treatment of Hepatitis C
Other Names:
  • Pegasys
Drug: Ribavirin
conventional treatment of Hepatitis C
Other Names:
  • Rebetol
Placebo Comparator: Placebo
placebo add on(t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
Drug: Peginterferon alfa-2a
conventional treatment of Hepatitis C
Other Names:
  • Pegasys
Drug: Ribavirin
conventional treatment of Hepatitis C
Other Names:
  • Rebetol
Drug: Placebo
Placebo, without acting ingredient.
Other Names:
  • Placebo, without acting ingredient.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
sustained virologic response (SVR) rate
Time Frame: 24 weeks after the end of treatment (EOT, 48 weeks)
undetectable HCV RNA 24 weeks after the EOT.
24 weeks after the end of treatment (EOT, 48 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Virologic response (VR)
Time Frame: at the EOT (48 weeks)
undetectable HCV RNA at the EOT.
at the EOT (48 weeks)
relapse rate
Time Frame: 24 weeks after the EOT
undetectable HCV RNA at the EOT followed by a positive HCV RNA level within 24 weeks after the EOT
24 weeks after the EOT

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

TCM Biotech International Corp.

Investigators

  • Principal Investigator: I-Shyan Sheen, MD, Chang Gung Memorial Hospital
  • Principal Investigator: Lai Wei, MD, Peking University People's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2015

Primary Completion (Anticipated)

March 1, 2018

Study Completion (Anticipated)

June 1, 2018

Study Registration Dates

First Submitted

June 26, 2013

First Submitted That Met QC Criteria

June 26, 2013

First Posted (Estimate)

July 1, 2013

Study Record Updates

Last Update Posted (Actual)

April 28, 2017

Last Update Submitted That Met QC Criteria

April 26, 2017

Last Verified

January 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TCM-700-02-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Hepatitis C

Clinical Trials on TCM-700C

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe